MedTrace Logo

Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00165477 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2010-03-10

No results posted yet for this study

Summary

\- The purpose of this study is to find out if the combination of lenalidomide and radiation therapy is effective in controlling tumor growth in patients with newly-diagnosed supratentorial glioblastoma or gliosarcoma.

Conditions

Interventions

DRUG

lenalidomide

Given orally once a day for 21 days followed by a 1 week rest period. Subject may continue to receive study drug as long as the disease does not worsen and they experience serious side effects

RADIATION

Radiation

Starting 4-7 days after the start of lenalidomide and given once a day, 5 days a week for 6-7 weeks

Sponsors & Collaborators

Principal Investigators

  • Patrick Y. Wen, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2007-11-30
Completion
2009-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00165477 on ClinicalTrials.gov